Fresenius Follows US Denosumab Filing With EU Acceptance

EMA Accepts Firm’s Applications For Biosimilar Rivals To Prolia And Xgeva

 
• By Dave Wallace
  
EMA
Fresenius has filed its denosumab biosimilars with the EMA

More from Biosimilars

More from Products